Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force
7 de Septiembre de 2023
Invitamos a leer el artículo: “Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force”, en la que colaboró la Doctora Luisa Rocha, Investigadora de Cinvestav Sede Sur
Autores: Stéphane Auvin, Aristea S Galanopoulou, Solomon L Moshé, Heidrun Potschka, Luisa Rocha, Matthew C Walker
Felicitamos al estudiantado y profesorado que contribuyeron en esta investigación por su arduo trabajo.
Abstract: Despite progress in the development of anti-seizure medications (ASMs), one third of people with epilepsy have drug-resistant epilepsy (DRE). The working definition of DRE, proposed by the International League Against Epilepsy (ILAE) in 2010, helped identify individuals who might benefit from presurgical evaluation early on. As the incidence of DRE remains high, the TASK1 workgroup on DRE of the ILAE/American Epilepsy Society (AES) Joint Translational Task Force discussed the heterogeneity and complexity of its presentation and mechanisms, the confounders in drawing mechanistic insights when testing treatment responses, and barriers in modeling DRE across the lifespan and translating across species. We propose that it is necessary to revisit the current definition of DRE, in order to transform the preclinical and clinical research of mechanisms and biomarkers, to identify novel, effective, precise, pharmacologic treatments, allowing for earlier recognition of drug resistance and individualized therapies.
Keywords: adult, mechanisms, model, pediatric, pharmacoresistance.